P550 Early 12-week ultrasound response to treatment, used as a predictor of response at 6 months in Crohn’s disease: A prospective cohort study

Halasz, Jennifer; Lu, Cathy; Kaplan, Gilaad G.; Tanyingoh, Divine; Seow, Cynthia H.; Panaccione, Remo; Devlin, Shane; Wilson, Stephanie R.; Novak, Kerri L.

doi:10.1093/ecco-jcc/jjx180.677

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After 2 weeks of variable treatment, absolute and relative reductions in BWT of 0.6–0.9 mm [11–16%] have been reported. 56 , 61 After 4 weeks the BWT was reduced to 0.3–1.3 mm, [5–23%], 22 , 30 , 56 after 12 weeks to 0.01–3.0 mm [0.2–43%], 16 , 17 , 21 , 27 , 29 , 30 , 34 , 56 , 76 after 6 months to 1.0–1.9 mm [17–34%], 34 , 56 , 76 after 1 year to 1.4–2.35 mm [22–34%], 21 , 30 , 34 , 77 and after 2 years to 2.0–2.2 mm [33–36%]. 18 , 19 Only one study investigated azathioprine monotherapy and found a non-significant reduction of 0.4 mm [6%] after 2 years.…”

Section: Resultsmentioning

confidence: 99%

Defining Transabdominal Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease: Systematic Review and Expert Consensus Statement

Ilvemark

Hansen

Goodsall

et al. 2021

Journal of Crohn's and Colitis

View full text Add to dashboard Cite

Background and aims No consensus exists on defining intestinal ultrasound response, transmural healing, or transmural remission in inflammatory bowel disease, nor clear guidance for optimal timing of assessment during treatment. This systematic review and expert consensus study aimed to define such recommendations, along with key parameters included in response reporting. Methods Electronic databases were searched from inception to July 26, 2021, using pre-defined terms. Studies were eligible if at least two intestinal ultrasound assessments at different time points during treatment were reported, along with an appropriate reference standard. The QUADAS-2 tool was used to examine study-level risk of bias. An international panel of experts (n=18) rated an initial 196 statements (RAND/UCLA process, scale 1-9). Two videoconferences were conducted, resulting in additional ratings of 149 and 13 statements, respectively. Results Out of 5826 records, 31 full-text articles, 16 abstracts, and one research letter were included. 83% (40/48) of included studies showed a low concern of applicability, while 96% (46/48) had a high risk of bias. A consensus was reached on 41 statements, with clear definitions of IUS treatment response, transmural healing, transmural remission, timing of assessment, and general considerations when using intestinal ultrasound in inflammatory bowel disease. Conclusions Response criteria and time-points of response assessment varied between studies complicating direct comparison of parameter changes and their relation to treatment outcomes. To ensure a unified approach in routine care and clinical trials, we provide recommendations and definitions for key parameters for intestinal ultrasound response to incorporate into future prospective studies.

show abstract